Shionogi Pharmaceutical Co., Ltd., headquartered in Osaka, announced that it has begun clinical trials to confirm the efficacy of the new coronavirus vaccine being developed by inoculating it between the ages of 12 and 19.
Shionogi is developing a new type of coronavirus vaccine called "recombinant protein vaccine," and has announced that it will apply for approval to the government as early as next month for a vaccine for adults.
According to the company, this clinical trial targets 350 people aged 12 to 19 years old, and whether the vaccine under development is given twice and the antibody level etc. rises to the same level or higher than when it is given to adults. It means to confirm.
The clinical trial started on the 14th of this month, and after that, a third vaccination will be given to see if the antibody level rises again when the booster vaccination is given.
The company is also planning to start clinical trials for younger age groups, 5 to 11 years old.
Shionogi says, "We will work toward early development and supply so that we can provide new options to people of all ages."